Skip to content

Understanding cancer · Guide · 12 min read

What Are Exacta and RGCC Tests, and What Should You Do After Getting Your Results?

Exacta and RGCC tests can provide additional information about your cancer diagnosis, however understanding what the results mean for you isn’t always straightforward. Verita Life’s guide explains how these tests differ, what the findings really mean, and how to discuss your results with your healthcare team to make decisions about what happens next for you.

Medically reviewed by Dr Abdulla El-Hossami, Group Chief Medical OfficerPublished Nov 3, 2026
Man sits on a black leather chair in a medical room, amongst other empty black leather chairs with plants and a window out of focus in the background. He sits opposite a medical professional in blue scrubs with PPE and a clip board.

What Are Exacta and RGCC Tests, and What Should You Do After Getting Your Results?

If you’ve had an Exacta or RGCC test, you may be wondering what your results mean and how they may decide your next steps.

Exacta and RGCC tests are two types of molecular tests that many cancer patients bring with them when they come to Verita Life, particularly those exploring a more personalised approach to cancer care. Both aim to provide additional information about an individual’s diagnosis: not just what cancer you have, but how your particular cancer behaves and what treatments it is likely to respond to.

The reports can contain a lot of technical detail, and knowing what to do with that information isn’t always straightforward. Understanding what your results can tell you, and, as well as where the limitations lie, are an important first step to starting the right treatment plan for you.

Here, we explain what each test actually does, what the results may tell you, and what to consider once you have the results in your hands.

What is an Exacta test?

Exacta is a tumour gene expression analysis. According to the laboratory that developed the test, it examines the molecular characteristics of a tumour across more than 20,800 genes. The aim is to provide further insight into the biological processes and gene mutations associated with a particular cancer and identify potential treatment options.

The thinking behind it sits within a well established idea in modern oncology, which recognises that cancers can differ at a molecular level even when they originate in the same organ. Understanding those differences can help clinicians to assess whether particular treatments may be relevant to an individual patient. Standard treatment protocols are built around the average patient with a given cancer type and do not always account for the individual genetic architecture of one person's tumour, which is part of the reason why a therapy that might work well for one patient may do little for another.

Comprehensive genomic profiling is a type of testing that examines a tumour’s genetic changes. It already has an established role in certain areas of precision cancer care, particularly where identifying specific molecular alterations can inform targeted treatment.

A 2023 review of comprehensive genomic profiling describes substantial evidence that identifying driver mutations can guide molecularly targeted treatment and, in some cases, may improve outcomes (Pankiw M. et al., 2023).

Exacta is positioned as one route to that kind of profiling, which compliments conventional staging rather than a replacement for it.

In practical terms, the results may inform discussions about:

  • Targeted therapies: Whether particular molecular findings are relevant to targeted cancer drugs.
  • Cytotoxic (chemotherapy) drug response: Flagging which conventional chemotherapy agents the cancer appears more or less likely to respond to.
  • Drug toxicity risk: Using inherited drug metabolism markers to suggest which therapies a patient may tolerate and which might carry a higher risk of side effects or adverse reactions.
  • Drug repurposing options: Exploring whether existing medicines not normally used for that cancer may be appropriate, which becomes important in recurrent or advanced disease that has progressed despite treatment.
  • Monitoring over time: Tracking tumour burden and treatment response over time, so early signs that a therapy is failing can be picked up sooner.

Exacta test results are typically reported back to the requesting oncologist within ten days of the laboratory receiving the sample, although the overall turnaround time will also depend on sample collection and transport.

What is an RGCC test?

RGCC cancer testing refers to a group of different tests; however, unlike tumour testing, certain RGCC tests use a blood sample, also known as a liquid biopsy, to examine circulating tumour cells (CTCs). The primary focus of the test is to monitor circulating tumour cells, the cancer cells that break away from a primary tumour and travel through the bloodstream.

Analysing circulating tumour cells is an active area of cancer research, with liquid biopsies becoming a routine part of testing for certain cancers, such as non-small cell lung cancer or colorectal cancer. CTCs are now recognised as a non-invasive way to gather real time information about a tumour and how it is responding to treatment (Vidlarova et al., 2024).

RGCC testing was developed by a laboratory that originated in Greece, which is why some patients and medical professionals refer to it as the Greek Test.

Rather than one test, RGCC is a family of them. The most common tests include:

  • Onconomics Plus: A test that assesses the response to a range of substances, including chemotherapy drugs, targeted agents, and natural compounds, perhaps the reason why it tends to appeal to people seeking an integrative plan rather than a single conventional protocol.
  • Oncotrail: Designed for specific, already diagnosed cancers, used to measure how aggressive the tumour is and to track it over time.
  • ArrayCGH: Used to identify chromosomal abnormalities, which can be helpful when the primary site of a cancer is unknown.
  • OncoCount: a more general measure that detects and quantifies circulating tumour cells in the blood, often used for ongoing monitoring.

These tests share the goal of working out which drugs, natural substances, and different therapies a patient's specific cancer cells appear sensitive or resistant to, narrowing a long list of possible treatments down to the ones most worth considering.

Although these tests share an interest in understanding cancer at a cellular or molecular level, they do not all measure the same things. For this reason it’s important to understand the purpose of the specific tests you have taken and what its findings can tell you with the help of expert interpretation.

It is also one of the best reasons to get a professional opinion on what a report like this recommends. If you want to understand your report better, you can book a call with us to discuss things further with our medical team.

What should you do after getting your RGCC or Exacta test results?

Receiving your report is one step, but understanding how it relates to your individual circumstances is another. A report is only as useful as the plan built from it, and the steps below are the ones that tend to matter most:

1. Seek guidance on interpreting your results

These reports can be detailed, but the summary recommendations may not tell the whole story. Gene findings, sensitivity scores, and other markers can be difficult to interpret without an understanding of the test methodology and its limitations.

The people best placed to translate your results and what they mean in “human” terms are integrative oncology specialists who read these reports regularly and are comfortable with both conventional and complementary approaches. Our medical team at Verita Life, for example, can help you to understand what your results mean and what the best next steps might be based on the findings.

2. Understand what the results can and can’t tell you

Underneath the complexity, these reports are usually answering three practical questions:

  • Which therapies does my cancer appear to respond best to?
  • What are the potential risks, limitations, or side effects of the treatments being considered, and how might they affect my unique case?
  • Are there unconventional options, such as the natural agents flagged in an Onconomics Plus panel, that might be worth exploring alongside standard care?

A specialist familiar with these reports can help you to make sense of the molecular details, explain what the findings mean for your situation, and guide you through the questions that matter most in plain language.

It is important to note that it is easy to assume these tests provide a definitive prognosis or guarantee a specific treatment outcome. In reality, they offer probabilistic sensitivities and biological insights to help inform and guide your care options rather than absolute promises.

3. Consider Integrative Oncology

Integrative oncology considers how different aspects of care may work together to support an individual patient, while recognising and complementing conventional oncology.

At Verita Life, we focus on looking at the person as a whole and tailoring a treatment plan with a combination of conventional and non-conventional treatments to suit them, prioritising individual effectiveness and unique needs.

Many of the patients we have spoken with over the past year had already completed one of these tests. From here, our team will seek to support our patients by including:

  • Having a call with the team to translate what the report is actually saying, helping them to understand the content and their next steps.
  • Offering a second opinion on the treatment recommendations themselves, weighed against conventional oncology guidance and the broader evidence, as well as our team’s many years of experience.

Clinics like Verita Life in Bangkok are set up for exactly this, building a personalised integrative protocol around your results, complementing conventional oncology care rather than substituting it. The team regularly works with patients from Australia and all over the world, who arrive with results and need a clear, evidence-informed path forward.

4. Prepare questions for your Oncologist

A few focused questions can help you make the most of your consultation. Three questions that we think are helpful to write down and take with you are:

  • Based on my molecular profile, which targeted therapies, if any, are the strongest match for my cancer?
  • Do my results show sensitivity to any natural agents or supportive therapies that could be used alongside my current treatment?
  • How will we use repeat testing to monitor whether the treatment is actually working over the coming months?

5. Use the results for monitoring, not just for planning

Depending on the test and your individual circumstances, repeat testing may help monitor changes over time. Completing the tests again later in treatment can help you and your medical team better understand whether a therapy is working, if tumour activity is falling, or whether the cancer is finding ways around the current treatment approaches.

Speak to your specialist about what a sensible retesting interval looks like for your unique situation.

Moving forward with your results

Getting your results not be the end of the journey, but it can help you start taking the first steps in making meaningful decisions about your care.

The good news is that you don’t have to navigate this alone. If you have recently received your Exacta or RGCC results and are not sure what they mean for you, Verita Life's Integrative Oncology team offers an initial consultation, at no cost or obligation, to talk through what your report is showing, what the recommendations really mean, and what a sensible next step might look like.

FAQs

Is the RGCC test the same as the "Greek Test"?

Yes. The informal term simply refers to the Greek laboratory the test originated from. It is the same family of tests described above.

Are Exacta and RGCC tests proven, or are they standard of care?

The science behind gene profiling and circulating tumour cell analysis is well established. The specific use of a blood sample to predict drug sensitivity is still considered investigational by many insurers and reviewers, with prospective trial evidence for survival benefit not yet established. They are still valuable but best understood as additional information to support treatment plan recommendations via an expert, rather than stand-alone tests

Do Exacta and RGCC tests replace the scans and biopsies my Oncologist already ordered?

No. Exacta and RGCC are intended to add a layer of molecular and cellular detail, working alongside conventional staging, scans, and standard pathology rather than replacing them.

Can I get advice built around results I already have?

Yes. Many patients order testing first and seek interpretation afterwards. Arriving with a completed report is a perfectly normal starting point for an integrative oncology consultation. Book a free consultation with our medical team.

References

  • Pankiw M. et al. (2023) 'Comprehensive genomic profiling for oncological advancements by precision medicine', Medical Oncology, Nov 22;41(1):1. DOI: 10.1007/s12032-023-02228-x
  • Allen, TA. (2024) 'The Role of Circulating Tumor Cells as a Liquid Biopsy for Cancer: Advances, Biology, Technical Challenges, and Clinical Relevance', Cancers, 16(7), 1377. DOI: 10.3390/cancers16071377
Share

Further reading

Understanding cancer

Dendritic Cell Therapy Explained

If you have been researching cancer treatments beyond chemotherapy, radiotherapy, and surgery, you have probably come across dendritic cell therapy. The name sounds technical but the science behind it is genuinely interesting. This article helps to answer a lot of the questions patients tend to arrive with: how does it actually work, is it effective, what are the side effects, and where does it fit alongside other integrative treatments?

9 min readBy Dr Abdulla El-Hossami

Understanding cancer

4 Methods to stay fit when fighting Cancer

Get your body back in fighting shape after cancer treatment. Here are 4 different ways to stay healthy while you fight cancer.

3 min read

Understanding cancer

Bladder Cancer Awareness Month

May is Bladder Cancer Awareness Month. The World Health Organisation ranks Bladder Cancer as the 12th most common cancer globally and estimates that 170,000 new cases are recorded each year with the developing countries recording a third of these.

3 min read

Patient sits in a black leather chair having a conversation with a medical professional in scrubs who is sitting in front of her.

Talk to the care team

A free consultation about your situation, by phone, WhatsApp, or video.

Book a consultationRegister